Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Drug-resistant infections are set to kill more people than cancer by 2050. Now a new University of Plymouth spinout company has been established to help tackle the problem - by developing new antibiotics and bringing them to market.
One man's trash is another man's treasure, as the saying goes. If things go to plan, feces from registered and thoroughly tested healthy donors will in a few years be the standard treatment for the bacterium Clostridium difficile at Danish hospitals.
Dr. Li Deng of Helmholtz Zentrum München has been awarded a Starting Grant of the European Research Council. The scientist intends to tackle antimicrobial resistance by fighting bacteria with their natural enemies - the viruses. The grant is endowed with nearly 1.5 million euros for five years.
Healthcare-associated infections can be reduced by up to 55 percent by systematically implementing evidence-based infection prevention and control strategies, according to a review of 144 studies published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
A naturally occurring antibiotic called kanglemycin A is effective against Mycobacterium tuberculosis, the bacteria that cause tuberculosis, even in drug-resistant strains, according to an international team of researchers who used chemistry, molecular biology, microbiology, and X-ray crystallography to show how the compound maintains its activity.
A team of researchers at the University of Cologne's Faculty of Medicine and the German Center for Infection Research has achieved a scientific breakthrough in the accelerated diagnosis of multi-resistant hospital pathogens.
Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding with Brazil-based Oswaldo Cruz Foundation 'Fiocruz' for the development of viral vaccines.
You can think of a cell in your body like a miniature factory, creating a final product called proteins, which carry out various tasks and functions.
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.
UTILITY therapeutics Ltd, a pharmaceutical company focused on developing and commercializing antibiotics in the US, today announces that the US Food and Drug Administration has approved the Investigational New Drug applications for mecillinam and pivmecillinam.
New research showing that the first bacteria introduced into the gut have a lasting impact may one day allow science to adjust microbiomes--the one-of-a-kind microbial communities that live in our gastrointestinal tracts--to help ward off serious chronic diseases.
Persons with Alzheimer's disease are more often hospitalized after antibiotic initiation than people without AD, a new study from the University of Eastern Finland shows.
Global demand exists for new ways to reduce antibiotic use, given the urgent public health threat of antibiotic resistance.
The bacteria Pseudomonas aeruginosa can cause serious and difficult to treat infections. The infection process involves the activation of toxic substances from the bacteria by a common protein in our cells.
A quick and easy test for viral infections can reduce unnecessary antibiotic use and hospital admissions, according to new research presented to the European Respiratory Society International Congress today.
A startling new study has found that regular use of probiotics in infancy can significantly reduce antibiotic prescriptions during childhood.
Bacteria are very sneaky in their efforts to develop resistance to antibiotics. Some strains of bacteria package up the genetic instructions for how they defend themselves and cause disease, and pass this information on to neighbouring, naïve, bacteria - essentially gifting their colleagues with the defences they need to survive against our medical armoury of antibiotics.
If you're looking into the mouth of a brown bear, one of the world's top predators, your chances of survival probably aren't good. But a team of Rutgers and other scientists has discovered a technology that rapidly assesses potentially lifesaving antibiotics by using bacteria in saliva from an East Siberian brown bear.
A £3 million interdisciplinary research project is to address the growing threat of drug-resistant infections in India. The project will develop innovative diagnostics to curb antimicrobial resistance (AMR), one of the biggest threats to global public health.